azlocillin and Aspergillosis

azlocillin has been researched along with Aspergillosis* in 1 studies

Other Studies

1 other study(ies) available for azlocillin and Aspergillosis

Article	Year
[Pulmonary aspergillosis in an immunocompetent female patient]. Deutsche medizinische Wochenschrift (1946), 1994, May-27, Volume: 119, Issue:21 Symptoms of bronchopneumonia developed over 4 months in a 63-year-old woman in previously good health. The symptoms worsened despite treatment with tetracycline (500 mg twice daily for 10 days). Middle-lobe pneumonia was diagnosed both clinically and radiologically, but monotherapy with ofloxacin (200 mg twice daily) was ineffective, as well as combined treatment with gentamycin (80 mg), oxacillin (1 g) and azlocillin (5 g), each three times daily intravenously. Bronchoscopy revealed obstruction of the lumen of the right middle lobe bronchus by viscous purulent secretion which contained a high count of Aspergillus fumigatus, previously found in several sputum samples. The inflammatory process regressed completely within 12 days on itraconazole (200 mg twice daily), combined with nystatin inhalation (100,000 IU five times daily). The only possible aetiologically significant risk factor in this immunocompetent woman could have been her frequent use of a bio-waste container. Topics: Administration, Inhalation; Aspergillosis; Aspergillus fumigatus; Azlocillin; Bronchi; Bronchoscopy; Drug Therapy, Combination; Female; Gentamicins; Humans; Immunocompetence; Itraconazole; Lung Diseases, Fungal; Medical Waste Disposal; Middle Aged; Nystatin; Ofloxacin; Oxacillin; Risk Factors; Sputum; Tetracycline	1994

Article

Year

[Pulmonary aspergillosis in an immunocompetent female patient].

Deutsche medizinische Wochenschrift (1946), 1994, May-27, Volume: 119, Issue:21

Symptoms of bronchopneumonia developed over 4 months in a 63-year-old woman in previously good health. The symptoms worsened despite treatment with tetracycline (500 mg twice daily for 10 days). Middle-lobe pneumonia was diagnosed both clinically and radiologically, but monotherapy with ofloxacin (200 mg twice daily) was ineffective, as well as combined treatment with gentamycin (80 mg), oxacillin (1 g) and azlocillin (5 g), each three times daily intravenously. Bronchoscopy revealed obstruction of the lumen of the right middle lobe bronchus by viscous purulent secretion which contained a high count of Aspergillus fumigatus, previously found in several sputum samples. The inflammatory process regressed completely within 12 days on itraconazole (200 mg twice daily), combined with nystatin inhalation (100,000 IU five times daily). The only possible aetiologically significant risk factor in this immunocompetent woman could have been her frequent use of a bio-waste container.

Topics: Administration, Inhalation; Aspergillosis; Aspergillus fumigatus; Azlocillin; Bronchi; Bronchoscopy; Drug Therapy, Combination; Female; Gentamicins; Humans; Immunocompetence; Itraconazole; Lung Diseases, Fungal; Medical Waste Disposal; Middle Aged; Nystatin; Ofloxacin; Oxacillin; Risk Factors; Sputum; Tetracycline

1994